Confidentiality Agreement: Why do you need it and what to consider before signing?

Key Takeaways

• A Confidentiality Agreement helps businesses share sensitive information in a controlled way to facilitate discussions regarding a larger deal or collaboration.

• It can support patent strategy and trade secret protection, but only if the company also applies real confidentiality measures in practice.

• Not every Confidentiality Agreement should look the same. An agreement to facilitate a research collaboration should differ from a deal-focused agreement.

• Even a strong Confidentiality Agreement has limits, so businesses should disclose carefully and keep records of what they share.

What is a Confidentiality Agreement?

A Confidentiality Agreement is a legal contract designed to protect sensitive information shared between parties. It may also be called an NDA or CDA, but the core idea is the same: one party, or both parties, want to exchange non-public information without allowing it to be leaked, misused or turned into a commercial disadvantage. It is the legal equivalent of opening the door only after deciding who gets the key. That is why it is often the agreement that allows serious discussions to begin to kick off a research collaboration, licensing deal, investment round or transaction. For IP- and patent-driven businesses, that first step matters because uncontrolled disclosure can weaken both legal protection and negotiating position.

A simple example is a company preparing to share early technical data with a potential partner before the parties are ready to sign a broader commercial agreement. The Confidentiality Agreement creates the legal framework for that exchange. It does not eliminate every risk, but it allows the conversation to move forward without treating disclosure as a leap into the dark.

When are Confidentiality Agreements necessary?

Confidentiality Agreements are necessary whenever a business needs to share commercially valuable non-public information before the full legal framework of the transaction or collaboration is in place. That includes many more situations than just classic M&A or patent licensing deals.

Typical examples include early-stage research collaborations, investment discussions, strategic partnerships, licensing negotiations, due diligence processes and technical discussions with potential manufacturers or service providers. A biotech company sharing preliminary drug trial data with a possible partner is a good example. Without a Confidentiality Agreement, it may be exposing information that is central to its future value while still being too early in the process to rely on a broader contractual framework.

It is also useful to distinguish between different types of Confidentiality Agreement. A research Confidentiality Agreement is often used where scientific information, methods and experimental data are shared over a longer period. That kind of arrangement may require more nuanced terms around permitted use, handling of research outputs and access to technical information. A deal Confidentiality Agreement is usually more transactional. It often focuses on business plans, valuation data and strategic information exchanged in connection with financing, licensing or acquisitions. Both are Confidentiality Agreements, but they do not always need the same drafting emphasis.

What does a Confidentiality Agreement typically contain?

The core elements of a Confidentiality Agreement usually include:

• Definition of confidential information: This clause defines what is protected. The definition should be broad enough to cover the actual disclosure, but not so broad that it becomes unclear or difficult to enforce. In some cases, it should also cover derived information, the fact that the parties are in discussions, and the existence or terms of the agreement itself. 

• Permitted purpose: This clause explains why the information is being shared and what the recipient may do with it. It should be drafted with care. A vague purpose such as “evaluating a potential business relationship” often leaves too much room for argument. A more specific purpose usually gives better protection. 

• Non-disclosure and non-use obligation: A good Confidentiality Agreement should not only prohibit disclosure to third parties. It should also prohibit internal use outside the permitted purpose. That point is often overlooked, but it is critical in practice. 

• Recipient circle and need-to-know access: This clause controls who inside the receiving organization may access the information. Access should usually be limited to employees, advisers or affiliates who genuinely need the information for the permitted purpose and who are bound by comparable confidentiality obligations. 

• Exclusions from confidentiality: Most agreements exclude information that is already public, was already known to the recipient, was independently developed, or was lawfully received from a third party. These carve-outs are standard, but they should not be drafted so broadly that they become easy escape routes. 

• Marking requirements, if any: Some agreements require information to be marked as confidential. From the disclosing party’s perspective, this can create practical problems, especially in meetings, email exchanges or ongoing project work. In many cases, a more flexible approach works better. 

• Protection standard: This clause sets the level of care required from the recipient, often at least reasonable care or the same care used for the recipient’s own confidential information. 

• Reverse engineering restriction: Where products, samples, software or technical materials are shared, it can be sensible to state expressly that reverse engineering is prohibited. Without clear contractual wording, this point may be less certain than many businesses expect. 

• Return, deletion and destruction: This clause addresses what happens when discussions end. It should deal with return or deletion of materials, while also taking into account practical complications such as backups, email archives and legal retention duties. 

• Term and survival: This determines how long confidentiality obligations last. The right period depends on the type of information. Deal data may justify a shorter period, while know-how and trade secrets often require longer protection. 

• No license or transfer of rights: This clarifies that disclosure does not grant ownership, license rights or freedom to exploit the information. In IP- and patent-heavy settings, this should never be left implicit. 

• Remedies: Many agreements address injunctive relief, damages and, in some cases, contractual penalties. These remedies matter because speed is often critical when confidential information is about to be misused or disclosed. 

For readers who want a deeper drafting guide, please check out our more detailed articles 10 Tips for Better CDAs, which you can find here and here.  

What are the practical benefits of a Confidentiality Agreement?

One benefit is support for patent strategy. Public disclosure of an invention before filing can damage patent protection. A Confidentiality Agreement reduces that risk by allowing technical discussions to take place in a controlled setting. For example, if a company shares details of a new drug delivery system with a potential research partner, the agreement can help prevent premature disclosure that might otherwise undermine the patent process.

Another benefit is the protection of know-how. Not all valuable information should be patented. Manufacturing processes, research methods and internal technical workflows are often more valuable as trade secrets. A Confidentiality Agreement helps preserve that value by restricting access and use.

It also strengthens the legal position if something goes wrong. If the other side breaches confidentiality, the agreement provides clear evidence that obligations existed and that the recipient knew the information was confidential and purpose-bound. That can make it easier to seek injunctive relief or damages.

In addition, a Confidentiality Agreement often is required to ensure statutory trade secret protection, as almost all jurisdiction this require adequate contractual protective measures in order for information to reach trade secret status. In Germany, for example, under the Trade Secret Act (“Geschäftsgeheimnisgesetz”), maintaining trade secret status requires demonstrating sufficient secrecy measures (“Geheimhaltungsmaßnahmen”). A Confidentiality Agreement is often one of those measures. 

Finally, a well-drafted Confidentiality Agreement helps avoid ambiguity. The clearer the agreement is about what is protected and what the recipient may do with it, the easier it becomes to prevent disputes and enforce the contract later.

What are the limits of a Confidentiality Agreement?

A Confidentiality Agreement is useful, but it is not a magic shield. It does not prevent all leaks and it does not guarantee that every breach can be proved. In many real disputes, the hardest issue is evidence. A company may suspect that its information was used, but still struggle to prove whether the other side relied on the disclosed material or reached the same result independently.

This is particularly difficult where misuse is subtle. A competitor may gradually absorb ideas, methods or processes without leaving a clear trail. That is why operational secrecy remains essential. Businesses should keep track of who received what, limit disclosure to what is actually necessary and avoid sharing crown-jewel information too early.

In other words: Not all information should be disclosed, even under a Confidentiality Agreement. If a formula, process or technical package is exceptionally sensitive, the safer approach may be to share only the minimum required to move the discussion forward. In practice, a company may disclose performance data while holding back the most sensitive technical details until later stages of the relationship.

How are Confidentiality Agreements enforced?

Confidentiality Agreements are enforced through proof of breach and access to legal remedies. To prove a breach, the disclosing party usually needs to show what information was shared, that it fell within the agreement, who received it and how it was used or disclosed contrary to the agreed purpose. That is one reason disclosure discipline matters so much. A controlled data room, marked documents and a reliable disclosure record can make enforcement far more realistic.

If a breach is established, the available remedies may include injunctive relief, damages and, in some cases, contractual penalties. Injunctive relief is often the most urgent remedy because it can help stop further disclosure or misuse. Damages may also be available, although proving financial loss is not always easy. Contractual penalties can be helpful in the right case, but they should be drafted carefully and should not be treated as a substitute for a broader enforcement strategy.

Where can readers find a starting point?

For practical guidance, check out our standard CDA template available in our toolkit, available here: bio.law/tools. A solid template saves time, creates internal consistency and helps businesses avoid basic drafting mistakes. Still, the agreement should always be reviewed in light of the specific transaction, the type of information involved and the relevant risk profile.